ReviewRecent patents on biotechnology2012
Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications.
Review in Recent patents on biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Poloxamer 188 (P188), A Potential Polymeric Protective Agent for Central Nervous System Disorders: A Systematic Review.Current neuropharmacology · 2022Pooled it
- Pathophysiology-guided biomarkers and therapeutics for precision trauma medicine in polytrauma with musculoskeletal injuries.Military Medical Research · 2026Review
- Stability, disperse and rheological properties of oil-in-water emulsions prepared using poloxamer 188-xanthan gum mixtures.RSC advances · 2026Article
- A PHMB-Functionalized Fully Absorbable Synthetic Matrix as a Novel Alternative to Biologics: Balancing Antibacterial Efficacy, Tissue Repair, and Safety.Bioengineering (Basel, Switzerland) · 2026Article
- Murine Neutrophil Chemotaxis Following Burn Injury with Poloxamer 188 Treatment in a Microfluidic Platform.bioRxiv : the preprint server for biology · 2026Article
- Poloxamer 188 alleviates cerebral ischemia-reperfusion injury in mice by reducing mitochondrial and lysosomal membrane damage.Neurosciences (Riyadh, Saudi Arabia) · 2025Article
- Active Transport of Therapeutic Triblock Amphiphilic Polymer Poloxamer 188 in Brain Endothelial Cells for Cellular Repair.Journal of biomedical science and engineering · 2025Article
- Article
- Cardioprotection by poloxamer 188 is mediated through increased endothelial nitric oxide production.Scientific reports · 2025Article
- Influence of Pluronic F68 on Size Stability and Acoustic Behavior of Monodisperse Phospholipid-Coated Microbubbles Produced at Room Temperature.ACS applied materials & interfaces · 2025Article
- CEST MRI detects antiretroviral drug toxicities in the developing mouse brain.Frontiers in pharmacology · 2025Article
- Layer-by-Layer Biopolymer-Coated Deformable Liposomes-In Situ Gel: A Hybrid Strategy for Enhanced Ocular Delivery of Itraconazole: In Vitro and In Vivo Appraisal.Gels (Basel, Switzerland) · 2024Article
- Encapsulation of Nanocrystals in Mannitol-Based Inhalable Microparticles via Spray-Drying: A Promising Strategy for Lung Delivery of Curcumin.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Prkd1 regulates the formation and repair of plasma membrane disruptions (PMD) in osteocytes.Bone · 2024Article
- Effects of poloxamer 188 on traumatic brain injury.Brain, behavior, & immunity - health · 2024Review
- Article
- Vepoloxamer improves functional recovery in rat after traumatic brain injury: A dose-response and therapeutic window study.Neurochemistry international · 2024Article
- Review
- Pharmacotherapeutic Approaches to Treatment of Muscular Dystrophies.Biomolecules · 2023Review
- Tyrosine-derived polymeric surfactant nanospheres insert cholesterol in cell membranes.Journal of colloid and interface science · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Maintenance of the integrity of the plasma membrane is essential for maintenance of cellular function and prevention of cell death. Since the plasma membrane is frequently exposed to a variety of mechanical and chemical insults the cell has evolved active processes to defend against these injuries by resealing disruptions in the plasma membrane. Cell membrane repair is a conserved process observed in nearly every cell type where intracellular vesicles are recruited to sites of membrane disruption where they can fuse with themselves or the plasma membrane to create a repair patch. When disruptions are extensive or there is an underlying pathology that reduces the membrane repair capacity of a cell this defense mechanism may prove insufficient and the cell could die due to breakdown of the plasma membrane. Extensive loss of cells can compromise the integrity and function of tissues and leading to disease. Thus, methods to increase membrane resealing capacity could have broad utility in a number of disease states. Efforts to find reagents that can modulate plasma membrane reseal found that specific tri-block copolymers, such as poloxamer 188 (P188, or Pluronic F68), can increase the structural stability and resealing of the plasma membrane. Here we review several current patents and patent applications that present inventions making use of P188 and other copolymers to treat specific disease states such as muscular dystrophy, heart failure, neurodegenerative disorders and electrical injuries, or to facilitate biomedical applications such as transplantation. There appears to be promise for the application of poloxamers in the treatment of various diseases, however there are potential concerns with toxicity with long term application and bioavailability in some cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.